Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Semaglutide wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (2)
Outcomes where both Flaxseed and Semaglutide have evidence — compare verdict strength side-by-side.
30g (about 3-4 tablespoons) of ground/milled flaxseed daily
with-meals
Ground / milled flaxseed
Prescription-only, clinician-titrated. Subcutaneous (Wegovy weight management: escalate to 2.4 mg once weekly; Ozempic diabetes: 0.5-2.0 mg once weekly). Oral (Rybelsus diabetes: 3-14 mg once daily). DO NOT self-dose.
any
Subcutaneous once-weekly injection (Ozempic / Wegovy)
8-12 weeks
8-12 weeks
12 weeks
First 1-2 weeks
Weeks to months
Months (titrated over 16-20 weeks)
Months to years
Especially during dose escalation
Effects of flaxseed supplements on blood pressure: A systematic review and meta-analysis of controlled clinical trial.
Clin Nutr (2016) · Meta analysis · n=1302
15 trials (19 treatment arms), 1302 participants
Potent antihypertensive action of dietary flaxseed in hypertensive patients.
Hypertension (2013) · Rct · n=110
Double-blind, placebo-controlled RCT, 110 patients, 6 months
Flaxseed supplementation on glucose control and insulin sensitivity: a systematic review and meta-analysis of 25 randomized, placebo-controlled trials.
Nutr Rev (2018) · Meta analysis
25 RCTs (30 treatment arms)
Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1).
N Engl J Med (2021) · Rct · n=1961
Double-blind RCT in 1,961 adults with obesity/overweight WITHOUT diabetes, randomized 2:1 to subcutaneous semaglutide 2.4 mg/week or placebo plus lifestyle for 68 weeks
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT).
N Engl J Med (2023) · Rct · n=17604
Large cardiovascular-outcomes RCT: 17,604 patients with preexisting cardiovascular disease and overweight/obesity but WITHOUT diabetes
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6).
N Engl J Med (2016) · Rct · n=3297
Pre-approval cardiovascular-safety RCT in 3,297 patients with type 2 diabetes at high cardiovascular risk, semaglutide (0.5/1.0 mg/week) vs placebo for 104 weeks
Semaglutide has a higher evidence score (8.5/10 vs 6.5/10) and wins in 2 of 3 categories.
No known interactions between Flaxseed and Semaglutide have been documented in our database. However, always consult a healthcare provider before combining supplements.